BRIEF published on 10/28/2025 at 13:20, 10 months 15 days ago BB Biotech surperforme avec de solides résultats au troisième trimestre 2025 Fusions Et Acquisitions BB Biotech T3 2025 Secteur Des Biotechnologies Indice NASDAQ Biotech
BRIEF published on 10/28/2025 at 13:20, 10 months 15 days ago BB Biotech Outperforms with Strong Q3 2025 Results Biotech Sector M&A BB Biotech Q3 2025 Nasdaq Biotech Index
PRESS RELEASE published on 10/28/2025 at 13:15, 10 months 15 days ago Edison issues report on BB Biotech (BION) Edison issues positive report on BB Biotech (BION) with strong Q325 results, outperforming its benchmark. Sector outlook remains favorable with M&A as key performance driver Edison M&A BB Biotech Outperforming Q325 Results
BRIEF published on 10/24/2025 at 07:05, 10 months 19 days ago BB Biotech AG Releases Interim Report Highlighting Significant Profit Increase Investment Company BB Biotech AG Interim Report Net Profit Increase Drug Developers
BRIEF published on 10/24/2025 at 07:05, 10 months 19 days ago BB Biotech AG publie un rapport intermédiaire soulignant une augmentation significative des bénéfices BB Biotech AG Société D'investissement Augmentation Du Bénéfice Net Rapport Intermédiaire Développeurs De Médicaments
BRIEF published on 10/24/2025 at 07:05, 10 months 19 days ago Surperformance de BB Biotech au troisième trimestre 2025 dans un contexte de reprise sectorielle BB Biotech Performances Du Troisième Trimestre 2025 Indice Nasdaq Biotechnology Thérapies À Base D'ARN Reprise Du Secteur
BRIEF published on 10/24/2025 at 07:05, 10 months 19 days ago BB Biotech's Q3 2025 Outperformance Amid Sector Recovery Sector Recovery BB Biotech Q3 2025 Performance Nasdaq Biotechnology Index RNA-based Therapeutics
PRESS RELEASE published on 10/24/2025 at 07:00, 10 months 19 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes interim report for the first nine months of 2025, reporting CHF 106 mn net profit. More details at report.bbbiotech.ch/Q325 Financial Results Investment Company Net Profit BB Biotech AG Interim Report
PRESS RELEASE published on 10/24/2025 at 07:00, 10 months 19 days ago BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery BB Biotech AG reports strong Q3 2025 performance with portfolio outperforming Nasdaq Biotech Index, driven by solid net profit, key company milestones, and strategic investments BB Biotech AG Interim Report Sector Recovery Q3 2025 Portfolio Outperformance
BRIEF published on 09/22/2025 at 07:05, 11 months 20 days ago BB Biotech Joins SPI ESG Index Biotechnology Swiss Exchange BB Biotech Sustainable Investing SPI ESG Index
Published on 09/12/2026 at 02:35, 11 hours 31 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 6 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 1 minute ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 41 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 6 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 36 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 51 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 56 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 22 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 51 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
